Komori
Occurring Fact4890Tsubota Laboratory IncorporatedPharmaceuticals

Notice Regarding the Recording of Non-operating Income (Subsidy Income)

Grant income of ¥35.519 million related to research and development activities and other activities was recognized as non-operating income in the first quarter of the fiscal year ending March 2027. The amount is reflected in the first-quarter earnings summary released on the same day.

Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
35519
¥ thousand
Wording
Definitive
How definitive the wording is.

Recognition of Non-operating Income (Grant Income)

Subject Entity

Tsubota Laboratory Incorporated (the Company)

Target Locations / Products

Research and development activities and other activities, including the femtech-related business

OccurrenceThe first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
This disclosure08/12/2026
Cause

The Company is utilizing various grant programs for research and development activities and other activities, including its femtech-related business.

Amount of Impact on Business Performance

¥35.519 million (non-operating income)

Accounting period in which recognized

The first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)

Impact on Earnings Forecast

This is reflected in the First-Quarter Earnings Summary for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated), released today.

Event that occurred
ItemDetails
Event nameRecognition of Non-operating Income (Grant Income)
Date of occurrenceThe first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
Subject EntityTsubota Laboratory Incorporated (the Company)
Target Locations / ProductsResearch and development activities and other activities, including the femtech-related business
CauseThe Company is utilizing various grant programs for research and development activities and other activities, including its femtech-related business.
Amount of Impact on Business Performance¥35.519 million (non-operating income)
Accounting period in which recognizedThe first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
Impact on Earnings ForecastThis is reflected in the First-Quarter Earnings Summary for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-consolidated), released today.
Items this document does not state (17)
Date recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company is utilizing various grant programs for research and development activities, including its femtech-related business.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of Non-operating Income (Subsidy Income) | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori